Literature DB >> 23752311

Meganuclease-mediated virus self-cleavage facilitates tumor-specific virus replication.

Engin Gürlevik1, Peter Schache, Anneliese Goez, Arnold Kloos, Norman Woller, Nina Armbrecht, Michael P Manns, Stefan Kubicka, Florian Kühnel.   

Abstract

Meganucleases can specifically cleave long DNA sequence motifs, a feature that makes them an ideal tool for gene engineering in living cells. In a proof-of-concept study, we investigated the use of the meganuclease I-Sce I for targeted virus self-disruption to generate high-specific oncolytic viruses. For this purpose, we provided oncolytic adenoviruses with a molecular circuit that selectively responds to p53 activation by expression of I-Sce I subsequently leading to self-disruption of the viral DNA via heterologous I-Sce I recognition sites within the virus genome. We observed that virus replication and cell lysis was effectively impaired in p53-normal cells, but not in p53-dysfunctional tumor cells. I-Sce I activity led to effective intracellular processing of viral DNA as confirmed by detection of specific cleavage products. Virus disruption did not interfere with E1A levels indicating that reduction of functional virus genomes was the predominant cause for conditional replication. Consequently, tumor-specific replication was further enhanced when E1A expression was additionally inhibited by targeted transcriptional repression. Finally, we demonstrated p53-dependent oncolysis by I-Sce I-expressing viruses in vitro and in vivo, and demonstrated effective inhibition of tumor growth. In summary, meganuclease-mediated virus cleavage represents a promising approach to provide oncolytic viruses with attractive safety profiles.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23752311      PMCID: PMC3776629          DOI: 10.1038/mt.2013.117

Source DB:  PubMed          Journal:  Mol Ther        ISSN: 1525-0016            Impact factor:   11.454


  45 in total

1.  A novel tumor-specific replication-restricted adenoviral vector for gene therapy of hepatocellular carcinoma.

Authors:  P L Hallenbeck; Y N Chang; C Hay; D Golightly; D Stewart; J Lin; S Phipps; Y L Chiang
Journal:  Hum Gene Ther       Date:  1999-07-01       Impact factor: 5.695

2.  Selectivity of oncolytic viral replication prevents antiviral immune response and toxicity, but does not improve antitumoral immunity.

Authors:  Engin Gürlevik; Norman Woller; Nina Strüver; Peter Schache; Arnold Kloos; Michael P Manns; Lars Zender; Florian Kühnel; Stefan Kubicka
Journal:  Mol Ther       Date:  2010-08-10       Impact factor: 11.454

3.  Construction of a recombinant adenovirus for efficient delivery of the I-SceI yeast endonuclease to human cells and its application in the in vivo cleavage of chromosomes to expose new potential telomeres.

Authors:  M Anglana; S Bacchetti
Journal:  Nucleic Acids Res       Date:  1999-11-01       Impact factor: 16.971

4.  Zinc-finger nucleases as a novel therapeutic strategy for targeting hepatitis B virus DNAs.

Authors:  Thomas J Cradick; Kathy Keck; Shannon Bradshaw; Andrew C Jamieson; Anton P McCaffrey
Journal:  Mol Ther       Date:  2010-02-16       Impact factor: 11.454

Review 5.  The case of oncolytic viruses versus the immune system: waiting on the judgment of Solomon.

Authors:  Robin J Prestwich; Fiona Errington; Rosa M Diaz; Hardev S Pandha; Kevin J Harrington; Alan A Melcher; Richard G Vile
Journal:  Hum Gene Ther       Date:  2009-10       Impact factor: 5.695

6.  Growth-inhibitory and tumor- suppressive functions of p53 depend on its repression of CD44 expression.

Authors:  Samuel Godar; Tan A Ince; George W Bell; David Feldser; Joana Liu Donaher; Jonas Bergh; Anne Liu; Kevin Miu; Randolph S Watnick; Ferenc Reinhardt; Sandra S McAllister; Tyler Jacks; Robert A Weinberg
Journal:  Cell       Date:  2008-07-11       Impact factor: 41.582

7.  Targeting of p53-transcriptional dysfunction by conditionally replicating adenovirus is not limited by p53-homologues.

Authors:  Florian Kühnel; Engin Gürlevik; Thomas C Wirth; Nina Strüver; Nisar P Malek; Martina Müller-Schilling; Michael P Manns; Amancio Carnero; Lars Zender; Stefan Kubicka
Journal:  Mol Ther       Date:  2009-12-29       Impact factor: 11.454

8.  Human hematopoietic stem/progenitor cells modified by zinc-finger nucleases targeted to CCR5 control HIV-1 in vivo.

Authors:  Nathalia Holt; Jianbin Wang; Kenneth Kim; Geoffrey Friedman; Xingchao Wang; Vanessa Taupin; Gay M Crooks; Donald B Kohn; Philip D Gregory; Michael C Holmes; Paula M Cannon
Journal:  Nat Biotechnol       Date:  2010-07-02       Impact factor: 54.908

9.  Molecular basis of engineered meganuclease targeting of the endogenous human RAG1 locus.

Authors:  Inés G Muñoz; Jesús Prieto; Sunita Subramanian; Javier Coloma; Pilar Redondo; Maider Villate; Nekane Merino; Marco Marenchino; Marco D'Abramo; Francesco L Gervasio; Sylvestre Grizot; Fayza Daboussi; Julianne Smith; Isabelle Chion-Sotinel; Frédéric Pâques; Philippe Duchateau; Andreu Alibés; François Stricher; Luis Serrano; Francisco J Blanco; Guillermo Montoya
Journal:  Nucleic Acids Res       Date:  2010-09-16       Impact factor: 16.971

10.  p53-dependent antiviral RNA-interference facilitates tumor-selective viral replication.

Authors:  Engin Gürlevik; Norman Woller; Peter Schache; Nisar P Malek; Thomas C Wirth; Lars Zender; Michael P Manns; Stefan Kubicka; Florian Kühnel
Journal:  Nucleic Acids Res       Date:  2009-05-14       Impact factor: 16.971

View more
  1 in total

Review 1.  Genome-editing Technologies for Gene and Cell Therapy.

Authors:  Morgan L Maeder; Charles A Gersbach
Journal:  Mol Ther       Date:  2016-01-12       Impact factor: 11.454

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.